Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00952393 · ClinicalTrials.gov registry record · Phase 1
Nicotinic Receptors and Schizophrenia
A Phase 1 study of Schizophrenia, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT00952393: Completed Phase 1 study of Schizophrenia, sponsored by VA Office of Research and Development.
NCT00952393 is a Phase 1 study of Schizophrenia that has completed, run by VA Office of Research and Development. The registered enrollment target is 10 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00952393, a Phase 1 study of Schizophrenia, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The study determines if a new preparation of a drug designed to treat schizophrenia is more slowly released into the body.
Primary Outcome
This is the plasma level of the drug as determined by high performance liquid chromatography.
Conditions Studied
Interventions
- DRUG Pharmacokinetic
Study Locations (1)
Colorado
- VA Eastern Colorado Health Care System, Denver - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
What the finished NCT00952393 record still lists
NCT00952393 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Pharmacokinetic is the first listed.
NCT00952393 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT00952393 about?
NCT00952393 is a clinical study titled "Nicotinic Receptors and Schizophrenia". The study determines if a new preparation of a drug designed to treat schizophrenia is more slowly released into the body.
What is the current status of trial NCT00952393?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2010-01. Estimated completion is 2014-10.
What conditions does trial NCT00952393 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00952393?
The interventions under investigation include: Pharmacokinetic (DRUG).
Who is sponsoring clinical trial NCT00952393?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00952393 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00952393's enrollment target sits among peer trials
10 309th of 315 higher than 4 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia